Analysts Leerink Partners highlight promising results of Merck (MRK) and Moderna’s (MRNA) personalized cancer vaccine in late-stage trial
Merck and Moderna's personalized cancer vaccine has shown promising results in a late-stage trial for melanoma, potentially paving the way for a new treatment option and positively impacting both companies' stock prices.